Efficacy versus safety: the dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease

Coronary and cerebrovascular atherothrombosis are the leading cause of mortality and morbidity worldwide. Novel antiplatelet agents have been established for the management of patients with clinically evident coronary atherothrombosis and are increasingly used in these patients. These agents, howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Iannopollo, Gianmarco, Camporotondo, Rita, De Ferrari, Gaetano M, Leonardi, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018317/
https://www.ncbi.nlm.nih.gov/pubmed/24851050
http://dx.doi.org/10.2147/TCRM.S39216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018317/
https://www.ncbi.nlm.nih.gov/pubmed/24851050
http://dx.doi.org/10.2147/TCRM.S39216

Ejemplares similares